Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers REDWOOD CITY, Calif., Sept.
Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint Analyses of the data, including prespecified exploratory endpoints, are ongoing SAN DIEGO --(BUSINESS WIRE)--Sep. 14, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE...
Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the
Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept.
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to
Independent DSMB Recommends MediWound’s EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the spinal fluid of more than 75% of people with ALS and has been shown to produce the
Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases
Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial King of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:...
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug development leader with over 30 years of experience spanning late-stage development operations and regulatory
CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing
Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year 1 Gotistobart demonstrated a median
GSK today announced positive results from the registrational phase I/II ARROS-1 trial
GSK today announced positive results from the registrational phase I/II ARROS-1 trial
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year locoregional control rate was 79%, one-year local progression-free survival
This announcement contains inside information 14 September 2026 Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer SERENA-4 trial did not meet primary objective of statistically significant improvement in progression-free survival, however a numerical improvement was observed...
Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion mutation NSCLC at a planned interim analysis PRINCETON, N.J., TOKYO, Japan,
Longer survival achieved with fewer severe treatment-related side effects versus comparator...
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7% 1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload...
New York, NY - September 11, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update....
CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:...
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the